Cargando…
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS
OBJECTIVE: To evaluate the efficacy and safety of onabotulinumtoxinA 100 U in noncatheterizing patients with multiple sclerosis (MS) with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO). METHODS: In this randomized, double-blind phase III study, patients received onabotulinum...
Autores principales: | Tullman, Mark, Chartier-Kastler, Emmanuel, Kohan, Alfred, Keppenne, Veronique, Brucker, Benjamin M., Egerdie, Blair, Mandle, Meryl, Nicandro, Jean Paul, Jenkins, Brenda, Denys, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105039/ https://www.ncbi.nlm.nih.gov/pubmed/30030330 http://dx.doi.org/10.1212/WNL.0000000000005991 |
Ejemplares similares
-
OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology
por: Ginsberg, David, et al.
Publicado: (2013) -
Erratum to: OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology
por: Ginsberg, David, et al.
Publicado: (2014) -
OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020) -
OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012) -
OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)